Clinical Trial Update: Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ICL670 to Deferoxamine in beta-thalassemia patients with transfusion-related iron overload has completed, reporting on safety and effica…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia

Drugs mentioned

• Deferoxamine (deferoxamine)
• ICL670

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Beta-Thalassemia | Phase 3 | Status: COMPLETED